Format

Send to

Choose Destination
Nat Commun. 2017 Jul 17;8:16073. doi: 10.1038/ncomms16073.

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.

Author information

1
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
2
Universidad Autónoma de Madrid, Arzobispo Morcillo 4, Madrid 28029, Spain.
3
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Darwin 3, Madrid 28049, Spain.
4
Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 31008 Pamplona, Spain.
5
University Clinic, University of Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), Pío XII, 55, 31008 Pamplona, Spain.
6
Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Pettenkoferstrasse 9, 80336 Munich, Germany.

Abstract

The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8+ T cells with a resident memory (Trm) phenotype correlates with improved survival. However, the interplay of circulating CD8+ T cells and Trm cells remains poorly explored in tumour immunity. Using different vaccination strategies that fine-tune the generation of Trm cells or circulating memory T cells, here we show that, while both subsets are sufficient for anti-tumour immunity, the presence of Trm cells improves anti-tumour efficacy. Transferred central memory T cells (Tcm) generate Trm cells following viral infection or tumour challenge. Anti-PD-1 treatment promotes infiltration of transferred Tcm cells within tumours, improving anti-tumour immunity. Moreover, Batf3-dependent dendritic cells are essential for reactivation of circulating memory anti-tumour response. Our findings show the plasticity, collaboration and requirements for reactivation of memory CD8+ T cells subsets needed for optimal tumour vaccination and immunotherapy.

PMID:
28714465
PMCID:
PMC5520051
DOI:
10.1038/ncomms16073
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center